Cheyenne Journal

Creative Bioarray DDA Platform Release In-vitro Screening Service to Accelerate Modern Drug Process

 Breaking News
  • No posts were found

Creative Bioarray DDA Platform Release In-vitro Screening Service to Accelerate Modern Drug Process

September 20
11:18 2019
DDA platform recently announces the new release of its in-vitro screening services, which aims to provide powerful support in the modern drug discovery process.

New York – Sep 20th, 2019 – DDA platform, as a leading division of Creative Bioarray, focuses on offering high quality biotechnology services to facilitate the development of drug discovery as well as more other pharmaceutical research. DDA platform recently announces the new release of its in-vitro screening services, which aims to provide powerful support in the modern drug discovery process.

Screening for drug targets against compound libraries is now the mature and effective method for identifying the chemical origin of drugs. At present, there are two broad types of screening, that is, the target-based screening and phenotypic screening. In which, target-based screening is used by recombinant techniques and genomics to determine molecular targets, while, with the sequencing of the human genome and ongoing genomic efforts, the number of molecular targets available for drug discovery is further increased. In phenotypic screening, drugs are identified without knowledge or bias toward specific molecular targets, first identifying their pharmacological effects in cells, tissues or animals.

“Each unique drug discovery challenge requires its own unique solution to provide an effective identification of safe and effective new drugs and successfully translate them into clinical applications,” said Hannah Cole, the marketing director of Creative Bioarray, she also said that, “Target-based methods have significant utility in compounds, but when recombinant systems fail to accurately capture important biological complexities, finding a phenotypic analysis system results in better conversion to clinical outcomes.”

In addition, High-throughput screening processes require highly demanding efforts to satisfy stringent standards of homogeneity, sensitivity, persistence, reproducibility, and miniaturization. With years of efforts and experienced in-house experts, Creative Bioarray is able to offer a broad selection of binding, enzymatic, or cell-based functional assays to satisfy various requirements for the process of drug discovery.

“Whatever you need these in-vitro screening services, or others such as the biochemical screening, high-content screening or cell line panel,” said Hannah Cole, “However, perhaps there is no single preclinical system can perfectly reflect all the complexity of human patients, but we can continue to make progress on the discovery and development of important new therapies by continually striving for better systems and better understanding. Regardless of the strategy used, the results obtained should translate preclinical science into meaningful treatments. Specializing in both standard and custom in vitro assays, we have made our responsibility and mission to provide high-quality, reproducible data, and flexible solutions.”

About DDA platform

As a mature division of Creative Bioarray, DDA platform definitely will be the ideal and reliable innovation partner in research endeavors. With the support of professional scientists and years of experience, we are capable to provide a knowledgeable, collaborative and flexible service to our clients so as to accelerated drug development and improved research quality for worldwide projects.

Media Contact
Company Name: Creative Bioarray
Contact Person: Hannah Cole
Email: Send Email
Phone: 1-631-619-7922
Address:45-1 Ramsey Road Shirley
City: Long Island City
State: New York
Country: United States
Website: http://www.creative-bioarray.com